Galangin (GLN) Suppresses Proliferation, Migration, and Invasion of Human Glioblastoma Cells by Targeting Skp2-Induced Epithelial–Mesenchymal Transition (EMT)

Yu Xiong,Xue Lai,Wei Xiang,Jie Zhou,Jizhong Han,Hao Li,Huajiang Deng,Luotong Liu,Jianhua Peng,Ligang Chen
DOI: https://doi.org/10.2147/ott.s264209
IF: 4
2020-09-01
OncoTargets and Therapy
Abstract:BACKGROUND: Galangin (GLN), a pure natural flavonoid compound found in plants, has been shown to exert anti-cancer effects against multiple cancer types, including glioma. However, its underlying molecular mechanism remains unclear. Epithelial-to-mesenchymal transition (EMT) performs an important function in the genesis and development of cancer. Skp2, a pivotal component of SCF<sup>Skp2</sup> E3 ubiquitin ligase, has been shown to function as an oncogene in GBM invasion that contributes to the EMT process. Thus, we explored whether GLN inhibited Skp2-mediated EMT and the mechanism underlying the Skp2 degradation pathway.METHODS: CCK-8 assay, wound healing assay and transwell assay were used to examine cell proliferation, migration, and invasion after treatment with or without GLN. RT-PCR and Western blotting analysis were performed to evaluate mRNA and protein expression, respectively. Co-immunoprecipitation was conducted to detect ubiquitinated Skp2 levels in vitro and in vivo after GLN treatment. Bioluminescence imaging was performed to examine the intracranial tumor size of U87 xenograft mice. Microscale thermophoresis (MST) experiment was used to detect interactions between Skp2 and GLN.RESULTS: GLN suppressed GBM cell growth, migration, and invasion, and also downregulated the expression of Skp2 and mesenchymal markers (Zeb1, N-cadherin, snail, vimentin) in vitro. Moreover, the overexpression of Skp2 in GBM cells decreased the effect of GLN on EMT. Furthermore, we demonstrated that GLN degraded skp2 protein through the ubiquitination proteasome pathway and directly interacted with skp2 protein, as shown through the MST assay.CONCLUSION: This study is the first to identify Skp2 as a novel target of GLN for the treatment of GBM and report of Skp2 protein degradation in a ubiquitination proteasome pathway. Results from our study indicated the potential of GLN for the treatment of GBM through ubiquitin-mediated degradation of Skp2.
oncology,biotechnology & applied microbiology
What problem does this paper attempt to address?
The problem that this paper attempts to solve is to explore the inhibitory effect of the natural flavonoid compound galangin (GLN) on the proliferation, migration and invasion of human glioblastoma (GBM) cells and its molecular mechanism. Specifically, the researchers hope to verify whether GLN exerts its anticancer effect by targeting Skp2 - mediated epithelial - mesenchymal transition (EMT), and further explore how GLN promotes the ubiquitination degradation pathway of Skp2 protein. ### Main research background and objectives 1. **Background**: - Glioblastoma (GBM) is a highly malignant brain tumor. Despite treatment with temozolomide (Temozolomide, TMZ) and radiotherapy, tumor recurrence is inevitable, and the median survival time of patients does not exceed 1.5 years. - EMT plays an important role in the occurrence and development of tumors, especially in promoting the growth, migration and invasion ability of tumor cells. - As a key component of SCFSkp2 E3 ubiquitin ligase, Skp2 plays the role of an oncogene in the GBM invasion process and is involved in the EMT process. 2. **Research objectives**: - Explore whether GLN can inhibit the Skp2 - mediated EMT process. - Reveal the mechanism by which GLN promotes the degradation of Skp2, especially through the ubiquitin - proteasome pathway. - Verify the inhibitory effect of GLN on the proliferation, migration and invasion of GBM cells in vitro and in vivo. ### Research methods - **Cell experiments**: The CCK - 8 method was used to detect cell viability, and the scratch - healing experiment and Transwell experiment were used to evaluate cell migration and invasion ability. - **Molecular biology techniques**: RT - PCR and Western blot were used to analyze the mRNA and protein expression levels, and Co - immunoprecipitation was used to detect the Skp2 ubiquitination level. - **Animal experiments**: An intracranial xenograft mouse model of the U87 cell line was constructed to evaluate the effect of GLN on tumor growth. - **Interaction detection**: The micro - scale thermophoresis (MST) experiment was used to detect the direct binding between GLN and Skp2 protein. ### Main findings - **In vitro experiments**: GLN significantly inhibits the growth, migration and invasion of GBM cells and down - regulates the expression of Skp2 and mesenchymal markers (such as Zeb1, N - cadherin, Snail, Vimentin). - **Skp2 over - expression experiment**: Skp2 over - expression weakens the inhibitory effect of GLN on EMT. - **Ubiquitination degradation**: GLN promotes the degradation of Skp2 protein through the ubiquitin - proteasome pathway and directly binds to Skp2 protein. - **In vivo experiments**: GLN inhibits tumor growth, prolongs the survival time of mice and down - regulates the expression of Skp2 and EMT - related markers in the intracranial xenograft mouse model. ### Conclusion This study for the first time confirms that Skp2 is a new target of GLN in the treatment of GBM and reveals the mechanism by which GLN degrades Skp2 through the ubiquitin - proteasome pathway. These results indicate that GLN has a potential anti - GBM effect and may become a new strategy for the treatment of GBM.